LIFE News and Press, aTyr Pharma Inc. From 03/19/24

2024-03-19 08:04:18 ET More on premarkets gainers & stock I Worry That WW International, Formerly Weight Watchers, May Not Survive WW International, Inc. (WW) Q4 2023 Earnings Call Transcript Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upg...

2024-03-14 23:37:06 ET aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Conference Call March 14, 2024, 17:00 ET Company Participants Ashlee Dunston - Director, IR & Corporate Communications Sanjay Shukla - President, CEO & Director Jill Broadfoot - CFO Co...

2024-03-14 16:04:29 ET More on aTyr Pharma Seeking Alpha’s Quant Rating on aTyr Pharma Historical earnings data for aTyr Pharma Financial information for aTyr Pharma Read the full article on Seeking Alpha For further details see: aTyr Pharm...

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™. ...

AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full yea...

Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT ™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT ™ study investigator and patient participant feedback. SAN DIEGO, Feb. 21, ...

2024-02-15 07:49:16 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecos...

Findings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique anti-inflammatory mechanism. Role of NRP2 in immune system validated by activity of NRP2 blocking antibody in preclinical models. SAN DIEGO, Jan. 29, 2024 (...

SAN DIEGO, Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appoi...